4MNA.F MINERVA NEUROSC. DL-0001

Healthcare Biotechnology Frankfurt Exchange
2.23 EUR
Close of Nov 11, 2026
1.87 6.80
Market cap
EUR 111M
P/E
-
P/B
2.60x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 4MNA.F undervalued?

Graham number

The Graham number of MINERVA NEUROSC. DL-0001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MINERVA NEUROSC. DL-0001 fundamental analysis

No fundamental analysis for MINERVA NEUROSC. DL-0001 yet.

MINERVA NEUROSC. DL-0001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MINERVA NEUROSC. DL-0001

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Full company profile